Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

343 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Conversion of patients with rheumatoid arthritis from the conventional to a microemulsion formulation of cyclosporine: a double blind comparison to screen for differences in safety, efficacy, and pharmacokinetics.
Anderson IF, Helve T, Hannonen P, Leirisalo-Repo M, Gilboe IM, Nissilä M, Keystone EC, Kraag GR, Bjørneboe O, Chalmers A, Dovland H, Mueller E, Richard F, Whatmough I, Schmidt AG, Kovarik JM. Anderson IF, et al. Among authors: keystone ec. J Rheumatol. 1999 Mar;26(3):556-62. J Rheumatol. 1999. PMID: 10090162 Clinical Trial.
Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial.
van der Heijde D, Keystone EC, Curtis JR, Landewé RB, Schiff MH, Khanna D, Kvien TK, Ionescu L, Gervitz LM, Davies OR, Luijtens K, Furst DE. van der Heijde D, et al. Among authors: keystone ec. J Rheumatol. 2012 Jul;39(7):1326-33. doi: 10.3899/jrheum.111171. Epub 2012 May 15. J Rheumatol. 2012. PMID: 22589265 Clinical Trial.
Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension.
Keystone EC, Breedveld FC, van der Heijde D, Landewé R, Florentinus S, Arulmani U, Liu S, Kupper H, Kavanaugh A. Keystone EC, et al. J Rheumatol. 2014 Jan;41(1):5-14. doi: 10.3899/jrheum.130543. Epub 2013 Nov 15. J Rheumatol. 2014. PMID: 24241487 Free article. Clinical Trial.
Intravenous golimumab in rheumatoid arthritis.
Cohen MD, Keystone EC. Cohen MD, et al. Among authors: keystone ec. Expert Rev Clin Immunol. 2014 Jul;10(7):823-30. doi: 10.1586/1744666X.2014.918847. Epub 2014 May 15. Expert Rev Clin Immunol. 2014. PMID: 24831189 Review.
343 results